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Parathyroid Gland Autoﬂuorescence Characteristics in Patients
With Primary Hyperparathyroidism
Richard H. Law, MD

; Katherine A. Larrabee, MD

; Meredith Van Harn, MS; Michael C. Singer, MD

Objective: Near-infrared imaging for intraoperative parathyroid gland (PG) detection has recently commanded signiﬁcant
attention. The PTeye (Medtronic, Minneapolis, MN) is a probe-based system for near-infrared autoﬂuorescent evaluation of PGs.
This study was designed to evaluate the capabilities of the PTeye in the setting of surgery for primary hyperparathyroidism.
Study Design: Prospective, Cohort study.
Methods: This single-institution, prospective cohort study included all patients undergoing parathyroidectomy for
primary hyperparathyroidism with presumed single gland disease from June 2020 to December 2020. Absolute intensity and
intensity ratios, with the thyroid as the control tissue, were obtained for the adenoma, ipsilateral normal PG, and adjacent tissue. The ability of the PTeye to function when not in direct contact with tissue was measured.
Results: Twenty-two patients were included. The median intensity ratio for the in situ adenomas was 4.38 (interquartile
range [IQR]: 2.03–5.87), ipsilateral normal PGs 6.17 (IQR: 3.83–7.67), strap muscle 0.47 (IQR: 0.30–0.60), and fat 0.20 (IQR:
0.17–0.47). All normal PGs and 21/22 adenomas demonstrated autoﬂuorescence above the detection threshold. The PTeye
functioned at a maximum distance of separation of 10 mm through saline medium and 6 mm through clear solid medium.
Conclusion: This study conﬁrms the PTeye’s ability to recognize PGs with a high degree of precision. The device was
found to function properly even with the probe not in direct contact with the tissue. Although adenomatous PGs appear to
demonstrate altered autoﬂuorescent properties from normal PGs, additional research is required to determine if these differences are clinically useful.
Key Words: PTeye, primary hyperparathyroidism, parathyroid gland, parathyroidectomy, autoﬂuorescence.
Level of Evidence: 3
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INTRODUCTION
Finding and recognizing parathyroid glands (PGs) is
a fundamental skill required for positive outcomes in both
thyroid and parathyroid surgery. For thyroidectomy, this
is the ﬁrst step in preserving these glands, necessary to
avoid postoperative hypoparathyroidism and hypocalcemia.1,2 In parathyroidectomy, identifying the PGs is compulsory for surgical success. However, this can be a
challenging and time-consuming endeavor, for even highly
experienced surgeons.3–8
The use of ﬂuorescence imaging technology to facilitate thyroid and parathyroid surgery has garnered significant clinical and research interest over the last several
years. The ability to view and evaluate PGs with nearinfrared (NIR) light seems to offer the prospect of overcoming some of the persistent challenges encountered
during these surgeries.
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Near-infrared imaging (NIRI) is currently being utilized in a number of ways to assess PGs. PGs possess a
particularly intense intrinsic ﬂuorescent nature that
when stimulated with the proper wavelength of light can
be seen with no augmentation or injected agent.1,2
Although the ﬂuorophore responsible for this autoﬂuorescent (AF) quality has not yet been identiﬁed, nearinfrared autoﬂuorescence (NIRAF) has been shown to be
effective at identifying PGs in the setting of both thyroid
and parathyroid surgeries.1,2
NIRI not reliant on AF, in which a contrast material
is injected to view the ﬂuorescence generated by blood
vessels of tissues, has also been investigated with PGs.
For visualization of the vascularity of PGs, indocyanine
green (ICG) is the preferred injection agent. In addition
to allowing for evaluation of the perfusion of the PGs,
ICG-enhanced NIRI can aid in their recognition.1,2
Several devices are available to surgeons to perform
NIRAF or NIRI. Camera-based systems, such as
Fluobeam (Fluoptics, Grenoble, France), offer a wide view
of the surgical ﬁeld and require limited pre-identiﬁcation
knowledge of the location of the PGs. As an alternative, a
probe-based system has been developed. The PTeye
device (Medtronic, Minneapolis, MN) is the only probebased system currently available. Rather than an image
on a screen showing varying degrees of brightness, the
PTeye provides an absolute measure of the degree of AF
of tissue (detection level) and a relative measurement of
AF compared to the AF of the thyroid gland (detection
Law et al.: Parathyroid Gland Autoﬂuorescence Patterns
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TABLE I.
Descriptive Statistics for All Variables.
Variable

Response

Total, N

22

Age (yr)

Mean (SD) or N (%)

62.3 (13.6%)

Sex

Male
Female

19 (86.4%)
29.7 (5.0)

No

DEXA T <

2.5 forearm

Concurrent thyroid surgery

28.1 (22.6, 40.8)

22 (100%)

Yes
History of kidney stones

64 (25, 83)

3 (13.6%)

Body mass index (kg/m2)
History of radioactive iodine

Median (Min, Max)

0 (0)

No

15 (68.2%)

Yes

7 (31.8%)

N/A

4 (18.2%)

No

6 (27.3%)

Yes

12 (54.5%)

No

19 (86.4%)

Yes

3 (13.6%)

Preoperative intact PTH (pg/mL)

125.9 (75.0)

Preoperative vitamin D2 (ng/mL)

31.4 (15.0)

28.5 (13.0, 74.0)

Preoperative ical (mmol/L)

1.39 (0.10)

1.38 (1.21, 1.62)

Corrected serum calcium (mg/dL)

10.9 (0.6)

Pre-incision ioPTH (pg/mL)

193.5 (140.1)

Postexcision ioPTH (15-min)

26.6 (10.9)

Maximum gland weight (mg)

1,270.7 (1,311.8)

115.0 (35.0, 357.0)

10.8 (9.9, 12.6)
156.1 (116.4, 208.8)
28.5 (8.4, 49.7)
595.0 (170.0, 5,000.0)

DEXA = dual-energy X-ray absorptiometry; ical = ionized calcium; ioPTH = intraoperative parathyroid hormone; Max = maximum; Min = minimum; N/
A = not available; PTH = parathyroid hormone; SD = standard deviation.

ratio [DR]).1,2 Tissue demonstrating a ratio of 1.2 or
greater has been shown with a high degree of sensitivity
and speciﬁcity to represent parathyroid tissue.6
Although the PTeye received Food and Drug Administration approval in November 2018, there is still limited
data available on the precise capabilities of the device.
Still even fewer studies have examined quantiﬁable differences between normal and adenomatous PGs. The primary aim of this study was to further explore the abilities
and limitations of the PTeye. This included assessment of
the PTeye’s capacity to measure AF when not in direct
contact with the tissue being interrogated. A secondary
aim of this study was to begin to evaluate possible quantiﬁable AF differences between normal and pathologic PGs.

MATERIALS AND METHODS
This was a single-institution, prospective cohort study of
22 patients undergoing parathyroidectomy for primary hyperparathyroidism from June 2020 to December 2020. The study
was approved by the Henry Ford Health System’s Institutional
Review Board (#14143). This study conforms to the ethical principles for medical research involving human subjects as described
in the Declaration of Helsinki.
All patients were conﬁrmed to have primary hyperparathyroidism with a range of indications for surgery. Inclusion criteria
for the study included co-localizing, preoperative imaging studies
highly suggestive of a single adenoma as the cause of the primary
hyperparathyroidism. All patients underwent focused parathyroidectomy. Patients discovered to have multi-gland disease intraoperatively were excluded from the study.

TABLE II.
Six-Month Postoperative Metrics.
Variable

Response

Total, N

15

Mean (SD) or N (%)

Median (Min, Max)

Postoperative intact PTH (pg/mL)

59.3 (29.9)

Postoperative vitamin D25 (ng/mL)

31.6 (10.9)

32.5 (12.0, 58.0)

Postoperative ical (mmol/L)

1.18 (0.05)

1.18 (1.07, 1.25)

9.6 (0.3)

9.6 (9.1, 10.2)

Postoperative corrected calcium (mg/dL)
Outcome

Cure
Incomplete

58.8 (28.0, 129.0)

15 (100%)
7 (46.7%)

ical = ionized calcium; Max = maximum; Min = minimum; PTH = parathyroid hormone; SD = standard deviation.
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TABLE III.
Autoﬂuorescence Intensities: Absolute and Ratios.
Variable

Response

Mean (SD)
31.1 (13.5)

33.0 (9.0, 56.0)

Absolute

127.3 (67.5)

123.5 (3.3, 242.0)

Thyroid AI baseline median
In situ adenoma AI

Ratio
In situ normal parathyroid gland

Absolute

4.7 (2.8)

4.4 (0.0, 12.4)

197.6 (84.0)

201.8 (35.7, 334.3)

Ratio
In situ strap muscle AI

Absolute

6.5 (3.0)

6.2 (2.3, 14.8)

13.8 (6.0)

12.7 (5.3, 27.0)

0.7 (1.3)

0.5 (0.1, 6.3)

Ratio
In situ fat AI

Absolute

10.2 (5.7)

8.8 (1.7, 26.7)

0.3 (0.2)

0.2 (0.0, 0.8)

175.0 (111.2)

150.5 (19.0, 443.0)

Ratio
Ex vivo adenoma AI (1-min)

Absolute
Ratio

Ex vivo adenoma AI (15-min)

Absolute

Median (Min, Max)

6.3 (4.4)

5.2 (0.4, 19.1)

192.4 (127.9)

171.8 (20.7, 539.3)

7.1 (5.3)

5.4 (0.5, 21.7)

Ratio

1-min = 1-minute postexcision; 15-min = 15-minute postexcision; AI = autoﬂuorescence intensity; Max = maximum; Min = minimum; SD = standard
deviation.

Information collected via chart review included patient
demographic information, symptoms, history of radioactive
iodine treatment, prior neck surgeries, preoperative, intraoperative, and postoperative laboratory values, and pathology
reports. All patients had ﬂuorometric readings taken via the
PTeye, which was used in the prescribed manner. The thyroid

A

median baseline intensity served as baseline comparison from
which the intensity ratios were calculated by the device. Both
detection level and DR were obtained for the following:
Adenoma in situ, the normal, ipsilateral PG, strap muscle, fat,
and the adenoma ex vivo 1 minute after excision and
15 minutes after excision.

Absolute autofluorescence intensity
Thyroid baseline
In-situ fat
In-situ strap muscle

In-situ normal parathyroid gland
In-situ adenoma
Ex-vivo adenoma (1-min)
Ex-vivo adenoma (15-min)
0

25

50

75

100

125

150

175

200

6

7

8

Mean autofluorescence intensity

B

Autofluorescence ratio
In-situ fat
In-situ strap muscle

In-situ normal parathyroid gland
In-situ adenoma
Ex-vivo adenoma (1-min)
Ex-vivo adenoma (15-min)
0

1

2

3

4

5

Mean autofluorescence ratio
Fig. 1. (A) Mean autoﬂuorescence intensity of examined tissues. Ex vivo adenoma is measured at 1-minute postexcision (1-min) and
15-minute postexcision (15-min). Thyroid tissue is measured at baseline prior to excision of the adenoma. (B) Ratio of autoﬂuorescence compared to thyroid tissue. [Color ﬁgure can be viewed in the online issue, which is available at www.laryngoscope.com.]
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Autofluorescence ratio
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3
2
1
0
5 mm
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2 mm

Normal saline

4 mm

6 mm

Silastic sheeting

Fig. 2. Mean autoﬂuorescence ratio of the excised adenoma in various settings. (1) The adenoma was submerged in saline of varying depths
(5, 10, 15, and 20 mm), (2) the adenoma was placed under clear silastic sheeting of varying depths (2, 4, and 6 mm). [Color ﬁgure can be
viewed in the online issue, which is available at www.laryngoscope.com.]

To assess the ability of the PTeye to work when not in
direct contact with the PG, a second data set was collected in
10 patients. In this phase of the study, the detection level and
DR of the excised adenoma were determined by the PTeye when
1) a blue surgical drape was placed directly in between the probe
and the adenoma, 2) the adenoma was submerged at the bottom
of a graduated cylinder with saline of varying depths (5, 10,
15, and 20 mm) separating the surface of the gland and the tip of
the probe, and 3) the adenoma was placed under clear silastic
sheeting of varying depths (2, 4, and 6 mm).

Surgical Technique
All patients included in the trial underwent a minimally
invasive (focused) parathyroidectomy. After the adenoma was
identiﬁed and assessed with the PTeye probe, it was excised. The
ipsilateral, normal PG was then found and interrogated with the
probe. Adjacent fat and strap muscle were subsequently tested
with the probe. In all cases, intraoperative parathyroid hormone
(ioPTH) levels were used to determine cure. The ioPTH criteria
employed were a drop of ≥50% from baseline, into the normal
range, and to a level less than 40 pg/mL. If the ioPTH levels did
not meet these standards, the remainder of the PGs were sought
and assessed.

Determination of Postoperative Cure
Cure was deﬁned by becoming eucalcemic and maintaining
calcium (ionized, serum, and corrected serum calcium) levels in
the normal range for ≥6 months from time of surgery.9 Persistence was deﬁned by continued hypercalcemia postoperatively
that did not normalize. Recurrent disease was characterized by a
period of eucalcemia that lasted at least 6 months following surgery, followed by a return of the hypercalcemia.9

Statistical Analysis
Continuous data are described using medians with 25th and
75th percentiles, whereas categorical data are presented using
counts and percentages. Univariate associations between continuous variables are carried out using Spearman’s rank correlation
coefﬁcients due to the small sample size and non-Gaussian distribution of the variables, which was examined using histograms,
Q-Q plots, and Shapiro–Wilk tests. Paired variables are compared
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using the nonparametric sign test. Statistical signiﬁcance is set
at P < .05. Measures of associations were performed for the AF
intensities/ratios of the adenomas and normal PGs to the other
variables. All analyses are performed using SAS 9.4 (SAS Institute Inc, Cary, NC). The study was conducted with a sample size
commensurate with previous studies.

RESULTS
There were 22 patients included in the study, of which
86.4% (19) were female. The median age was 64 years
(interquartile range [IQR]: 57–74) and body mass index
was 28.1 kg/m2 (IQR: 25.0–33.6) (Table I).
All patients met ioPTH criteria for cure after removal
of a single adenoma. Adenomas were conﬁrmed by histopathology. At 1-month follow-up, all patients achieved
eucalcemia. Fifteen patients remained cured >6 months
from time of surgery, whereas seven patients have not yet
reached their 6-month follow-up window (Table II). At
6 months, the patients demonstrated a mean PTH level at
the high-end of the normal range. Critically, however, all
patients continued to be eucalcemic.
The median preoperative intact PTH level was
115 pg/mL (IQR: 83–150), vitamin D level was 28.5 ng/mL
(IQR: 18–41), and ionized calcium was 1.38 mmol/L (IQR:
1.32–1.42). The median pre-incision ioPTH was 156.1 pg/
mL (IQR: 116.4–208.8) and the median postexcision ioPTH
at 15 minutes was 28.5 pg/mL (IQR: 19.1–34.2). The
median adenoma weight was 595 mg (IQR: 250–2,000).
The median thyroid baseline NIRAF detection level
was 33 (IQR: 19–39) (Table III). The median DR for the
parathyroid adenoma in situ was 4.38 (IQR: 2.03–5.87),
ipsilateral normal PG 6.17 (IQR: 3.83–7.67), strap muscle
0.47 (IQR: 0.30–0.60), fat 0.20 (IQR: 0.17–0.47), ex vivo
adenoma at 1 minute 5.15 (IQR: 3.03–8.43), and ex vivo
adenoma at 15 minutes 5.35 (IQR: 2.67–11.13). The detection levels were also recorded (Fig. 1). The median differential in DR between the adenoma and normal PG in situ
was 1.85 (IQR: 0.33–3.77). The overall sensitivity and
speciﬁcity of the device for normal and abnormal PGs was
97.7% and 100%.
Law et al.: Parathyroid Gland Autoﬂuorescence Patterns

All nonpathologic PGs demonstrated AF DR > 1.2
(minimum of 2.3), which is the threshold for detection of
parathyroid tissue. Twenty-one of 22 adenomas also
showed AF ratios >1.2. These AF levels were maintained
ex vivo. One adenoma demonstrated almost no AF
response. In 5/22 (22.7%) cases, the adenoma AF response
was greater than the normal, ipsilateral PG.
Univariate correlations were made between the
NIRAF level or ratio and clinical measures as shown in
Supporting Table S1.
The median DR of the adenoma under the blue surgical drape was 1.10 (IQR: 0.63–1.47). The median DR of
the adenoma under 5, 10, 15, and 20 mm of saline was
3.30 (IQR: 1.47–4.20), 1.10 (IQR: 0.83–1.90), 0.60 (IQR:
0.23–0.73), and 0.42 (IQR: 0.20–0.50), respectively. The
median DR of the adenoma with 2, 4, and 6 mm of intervening silastic sheeting was 4.17 (IQR: 2.50–5.93), 2.88
(IQR: 2.20–3.70), and 2.00 (IQR: 1.30–3.50), respectively (Fig. 2).

DISCUSSION
The use of NIRI with or without ICG injection for
intraoperative PG detection and assessment has gained
popularity in recent years. Although the technology is not
new, its application in the setting of thyroid and parathyroid surgery is relatively novel. The potential to reduce
the rates of post-thyroidectomy hypoparathyroidism and
ease the challenge of ﬁnding PGs and achieving cure in
parathyroidectomy has elicited much excitement among
surgeons performing these surgeries. However, there are
many nuances in the applications of these technologies
that are yet to be discovered and research is required to
better understand their precise capacities and beneﬁts.10
Much of the available research on NIRI has been
performed utilizing camera-based systems. These
camera-based systems, such as the Fluobeam devices,
provide a wide view and can be used with ICG enhancement to not just detect PGs but also evaluate their vasculature and perfusion. As with any new technology,
surgeons require some training to understand how to
interpret the acquired images. One signiﬁcant current
limitation of the camera-based systems is they do not
allow for real-time quantiﬁcation of ﬂuorescence. In the
absence of quantiﬁcation, a subjective scoring system of
the degree of ﬂuorescence, described by Vidal Fortuny
et al., is widely employed when using ICG injection for
PGs.11–13
The PTeye is the only Food and Drug Administrationapproved, probe-based system for NIRAF evaluation of
PGs. As the device does not provide a broad NIRI “view” of
the ﬁeld, it does require surgeons to have a greater knowledge of the likely location of PGs. One signiﬁcant advantage
of the PTeye is that it provides quantiﬁed data, allowing a
more objective measure of NIRAF. Earlier studies by the
research group at Vanderbilt University have established a
reference DR threshold for parathyroid tissue.14 McWade
et al. showed that a NIRAF ratio ≥ 1.2 compared to the thyroid was highly indicative of parathyroid tissue.6 A second
beneﬁt of the PTeye compared to the camera-based system
is its small proﬁle. Unlike a camera-based system, wide
Laryngoscope 00: 2021

exposure is not needed for the PTeye, making it more userfriendly, particularly for minimally invasive cases.
Several studies have shown the accuracy of the
PTeye at identifying parathyroid tissue. The sensitivity,
speciﬁcity, and overall accuracy of the PTeye in these
studies has been reported to be >90%.2,4,15
In regard to sensitivity and speciﬁcity, our results
are consistent with earlier studies. The PTeye accurately
identiﬁed all normal PGs, fat, and strap muscles. All fat
and muscle demonstrated almost no AF response. An
interesting ﬁnding brought up in prior studies is that
there can be a high false positive rate due to colloid nodules.16 That was not the case in this series, as the false
positive rate was 0%. Although a small series, the positive predictive value in this study was 100%. Despite previous reports that abnormal PGs do not demonstrate the
same degree of NIRAF as normal PGs, in our series 21/22
(95.5%) of adenomas produced an AF DR above the
threshold for parathyroid tissue.
This high degree of accuracy of the PTeye system
raises several important considerations. Currently, the
gold standard to intraoperatively conﬁrm tissue as parathyroid is frozen section biopsy. Alternatively, some surgeons will aspirate the tissue in question and send this
for ioPTH levels. Both of these approaches have associated costs and require time to be processed. Some have
suggested the possibility of using NIRAF as an “optical
biopsy” of the PGs. Given the ﬁndings of this and prior
studies, surgeons can consider employing the PTeye as a
more rapid, less invasive manner of conﬁrming the presence of parathyroid tissue. This could potentially have a
signiﬁcant impact on both parathyroid and thyroid surgeries. Given the real-time feedback of this device, bilateral neck explorations for parathyroid disease, for
example, may be performed in a faster manner. Anecdotally, surgeons have reported this experience although this
possible time saving has not yet been studied rigorously.
One major concern that has been raised about the
capability of NIRAF for PG identiﬁcation is the penetrating ability of the technology. PGs are often covered by fat,
fascia, or other soft tissue. The capacity of the PTeye
(or any NIRAF device) to adequately stimulate and
receive an AF response when tissue is overlying the PG is
unknown. Unfortunately, trying to rigorously quantify
this ability in a surgical ﬁeld, while eliminating confounding factors, is difﬁcult. To begin to evaluate this
question, we examined the PTeye’s ability to measure AF
when separated from the PG by known depths of saline
and heights of silastic sheets. This experiment clearly
does not replicate genuine surgical conditions. However,
to our knowledge this is the ﬁrst study that reveals that
the PTeye does not need to be in direct contact with the
PG to function appropriately. The maximum distance at
which proper detection still occurred in a normal saline
medium was found to be around 10 mm and about 6 mm
through a clear solid medium (although larger thicknesses were not tested). Although these materials do not
represent the equivalent scenario in situ, these ﬁndings
give surgeons additional knowledge of how to best use the
device and how to interpret the intensities and ratios.
This ability to function at a distance (at least through
Law et al.: Parathyroid Gland Autoﬂuorescence Patterns
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clear mediums) may signiﬁcantly impact how this device
can be used in thyroid and parathyroid surgeries.
Much of the current data on the use of NIRI for
intraoperative PG detection have been obtained in the setting of thyroid surgery for various pathologies, with some
focus on hyperparathyroidism.3,6,14,15,17–22 But the potential
beneﬁts of this technology in parathyroid surgery are self
evident. Identiﬁcation of PGs during parathyroidectomy,
the fundamental requirement for successful outcomes, presents a signiﬁcant challenge in some cases. In theory, the
ability of NIRAF to facilitate intraoperative localization of
PGs could represent a major step forward in parathyroidectomy. The ability to discriminate between normal and
abnormal PGs, which in some cases can be nuanced and
challenging, is a second crucial skill needed in parathyroidectomy. Characterizing the NIRAF qualities of pathologic
PGs is needed to understand whether NIRAF can possibly
aid as an adjunct to address this challenge of
differentiation.
To date, the research on the NIRAF characteristics
of pathologic PGs has reported somewhat inconsistent
ﬁndings. However, a number of studies have reported
that pathologic PGs demonstrate lower AF compared to
normal PGs.1,7,14,23,24 This may be due to differences in
the concentration of the ﬂuorophore, which has not yet
been identiﬁed, present in pathologic versus normal PGs.
The calcium sensing receptor (CaSR) of PGs has been proposed as the possible ﬂuorophore. Potentially, the lower
concentration of CaSRs in adenomas is the explanation
for their lower AF responsiveness.
Importantly, most of the investigations of pathologic
PGs have been performed using camera-based NIRAF.
As previously mentioned, due to the lack of quantitative
feedback, these studies are based on subjective reporting.
In addition to a possible altered degree of AF, a number
of studies have described anecdotally that there
appears to be increased AF heterogeneity displayed by
adenomatous PGs.
Our results regarding the AF nature of adenomatous
PGs are more mixed than prior studies. In this series,
many adenomas had lower median and mean DR compared with normal glands. However, the quantitative
nature of the PTeye allowed for greater stratiﬁcation of
these results. Interestingly, 22.7% (5/22) of patients had
adenomas that had higher NIRAF responsiveness than
that of the ipsilateral normal gland. In one patient, the
parathyroid adenoma demonstrated almost no AF despite
extensive interrogation of the whole surface of the gland.
After dividing this gland, the inside of the gland also did
not show any AF. No “cap” of tissue with higher AF
responsiveness was found.1 Although a majority of glands
in this study did show lower AF compared to normal PGs,
a signiﬁcant minority did not. This is an important ﬁnding as it suggests that using a relatively lower DR cannot
be used reliably to help discriminate between normal and
pathologic glands. As has been reported in prior studies,
anecdotally we noted that adenomas tended to demonstrate a signiﬁcant degree of heterogeneity. Perhaps if
quantiﬁable, this feature of adenomas may be exploited
in the future as a tool for differentiation. Research
endeavors are ongoing to assess this possibility further.
Laryngoscope 00: 2021
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CONCLUSION
The advancement of NIRAF technology in the setting of thyroid and parathyroid surgeries has been exciting. To fully optimize the use of this technology, the
precise capabilities and limitations of these devices and
approaches must be delineated. This study provides further evidence of the sensitive and speciﬁc ability of the
PTeye system to conﬁrm the presence of parathyroid tissue. Given this high accuracy, surgeons can consider
using the PTeye in lieu of frozen section biopsy. Importantly, this series also demonstrates that to function
properly the probe does not need to be in direct contact
with the tissue being assessed.
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